-
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
10 May 2024 18:00 GMT
… move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed …
$30.9K
89
50
About Gilead Sciences
Gilead Sciences develops and markets therapies to … between overbought and oversold.
Anticipated earnings release is in 83 days …
-
Gritstone bio, Inc. (NASDAQ:GRTS) Q1 2024 Earnings Call Transcript
10 May 2024 19:03 GMT
… , Inc. (NASDAQ:GRTS) Q1 2024 Earnings Call Transcript May 9, 2024 … from other leading players, including Gilead Sciences for therapeutic vaccine for HIV …
-
Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?
08 May 2024 22:22 GMT
… first quarter, VRTX’s earnings per share was 17.2% … surprise that VRTX’s strong earnings have topped the EPS … and the potential for future earnings growth.
Hence, we believe … are Sino Biopharmaceutical Limited (SBHMY), Gilead Sciences, Inc. (GILD), and Otsuka …
-
Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf
10 May 2024 16:36 GMT
Petosemtamab in Kombination mit Pembrolizumab bei 1L (Erstlinientherapie) HNSCC – erste vorläufige klinische Daten auf der ASCO-Jahrestagung 2024; Vorbereitung einer möglichen Phase-III-Studie
Zeno-BLA zur vorrangigen Prüfung durch die FDA für die …
-
Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
10 May 2024 16:36 GMT
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ; éventuel essai de phase III en préparation
Examen prioritaire …
-
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
10 May 2024 17:31 GMT
… disease therapy Lyfgenia. In an earnings update Thursday, the company disclosed … setback in September. — Ben Fidler
Gilead Sciences and partner Arcellx on Thursday …
-
US open: Dow continues to rally, Nasdaq heads south
10 May 2024 17:44 GMT
… markets amid a strong Q1 earnings season and following softer-than … . (KLAC) $720.78 1.42%
Gilead Sciences Inc. (GILD) $65.48 1 …
-
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
09 May 2024 20:01 GMT
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients
Conference call scheduled for today at 4:30 p.m. ET
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX …
-
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
09 May 2024 11:01 GMT
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback
HB-200 program …
-
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
08 May 2024 20:15 GMT
… preclinical development. Gilead Sciences
In March 2024, Merus and Gilead Sciences announced a … offset by equity investment from Gilead Sciences. Collaboration revenue for the … on account, accretion of investment earnings and net foreign exchange ( …